NCT00818480

An Extension Study Administering YM155 to Subjects Previously Enrolled in Another Protocol Administering YM155

Phase II: An Open-Label Extension Study of 168-Hour Continuous Infusion of YM155 in Subjects Previously Enrolled in a Phase I or Phase II Protocol Administering YM155

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 10 (actual)
• Sponsor: Astellas Pharma Inc · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This protocol is open to subjects previously enrolled in and who had completed a Phase I or Phase II study administering YM155. Subjects who are receiving benefit from treatment with YM155 are eligible after completing the previous study.

Detailed description

The main objective of the study is to continue to evaluate the safety and efficacy of YM155. Each subject will be treated at the dose he/she was receiving at the completion of his/her previous phase I or phase II YM155 study.

Conditions

• Prostate Cancer
• Melanoma
• Non-Hodgkin's Lymphoma

Interventions

Type	Name	Description
DRUG	YM155	continuous infusion

Timeline

• Start date: 2006-02-01
• Primary completion: 2011-03-01
• Completion: 2012-08-01
• First posted: 2009-01-07
• Last updated: 2015-09-04

Locations

3 sites across 1 country: United States